{"protocolSection":{"identificationModule":{"nctId":"NCT04890353","orgStudyIdInfo":{"id":"haojunwei4"},"organization":{"fullName":"Xuanwu Hospital, Beijing","class":"OTHER"},"briefTitle":"Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke","officialTitle":"Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"TERMINATED","whyStopped":"The interim analysis of another associated study is not very effective","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-12-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-02-08","type":"ACTUAL"},"completionDateStruct":{"date":"2023-02-28","type":"ACTUAL"},"studyFirstSubmitDate":"2021-05-11","studyFirstSubmitQcDate":"2021-05-17","studyFirstPostDateStruct":{"date":"2021-05-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-24","lastUpdatePostDateStruct":{"date":"2023-10-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xuanwu Hospital, Beijing","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in in alleviating neurologic deficits in patients with Acute Ischemic Stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Dimethyl Fumarate","acute ischemic stroke","immune modulation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"standard management plus Dimethyl Fumarate","type":"EXPERIMENTAL","interventionNames":["Drug: Dimethyl fumarate"]},{"label":"standard management","type":"NO_INTERVENTION"}],"interventions":[{"type":"DRUG","name":"Dimethyl fumarate","description":"Dimethyl fumarate 240mg orally twice daily for 3 consecutive days","armGroupLabels":["standard management plus Dimethyl Fumarate"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 7"},{"measure":"Lesion Volume","description":"Measured by MRI.","timeFrame":"day 7"}],"secondaryOutcomes":[{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day1"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day3"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day7"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day14"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day90"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 1"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 3"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 14"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 90"},{"measure":"Lesion Volume","description":"Measured by MRI.","timeFrame":"day 1"},{"measure":"Lesion Volume","description":"Measured by MRI.","timeFrame":"day 3"},{"measure":"Lesion Volume","description":"Measured by MRI.","timeFrame":"day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. \\>18 y of age;\n2. acute onset of focal neurological deficit consistent with acute ischemic stroke;\n3. measurable neurological deficit (NIHSS â‰¥ 5);\n4. anterior-circulation ischemic stroke defined by magnetic resonance angiography (MRA) and Diffusion-Weighted Imaging(DWI);\n5. onset of symptom to admission more than 4.5 h and less than 72 h. Patients who arrived within 0-4.5 h poststroke were treated with other medications according to the best accepted medical treatment guidelines.\n\nExclusion Criteria:\n\n1. Other diseases of the central nervous system\n2. There has been neurological disability in the past (mRS score\\>2)\n3. Difficulty swallowing\n4. Arrhythmia, atrioventricular block\n5. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs\n6. Macular edema\n7. MRA shows vertebral basilar artery obstruction\n8. Hemorrhagic stroke\n9. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product\n10. Pregnant and lactating women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Xuanwu Hospital, Capital Medical University","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069462","term":"Dimethyl Fumarate"}],"ancestors":[{"id":"D000003879","term":"Dermatologic Agents"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M2854","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M431","name":"Dimethyl Fumarate","asFound":"Periodontal treatment","relevance":"HIGH"},{"id":"M6764","name":"Dermatologic Agents","relevance":"LOW"},{"id":"M9902","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Derm","name":"Dermatologic Agents"}]}},"hasResults":false}